The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: uveitis following therapy with an immune checkpoint inhibitor
Parameters:
(1) type of uveitis
(2) cellularity of viteous fluid
(3) best corrected visual acuity
|
Type
|
Cellularity
|
Visual Acuity
|
Grade
|
|
anterior
|
none or trace
|
usual
|
G1
|
|
anterior
|
1+ or 2+
|
usual
|
G2
|
|
anterior
|
3+ or greater
|
minor changes
|
G3
|
|
intermediate posterior or panuveitis
|
NA
|
minor changes
|
G3
|
|
NA
|
NA
|
20/200 or worse
|
G4
|
The diagnosis requires exclusion of other causes of uveitis.
